Our results suggest that distinct mechanisms trigger glial activation at different preclinical Alzheimer’s disease stages in response to Aβ or tau pathology, which may lead to transient increments in imaging markers considered to reflect neurodegeneration. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.